Minutes of the thirty-fifth meeting
Held at 4045 Côte-Vertu Blvd., Saint-Laurent, in the Boardroom, on Wednesday, October 3, 2001, at 2:00 PM (translation)
1. Opening of meeting
2. Adoption of agenda
It was proposed, duly seconded and unanimously resolved that the agenda be adopted with the following additions to Miscellaneous:
8.7 Stable product budget - recommendation from the Canadian Hemophilia Society
3. Adoption of minutes of the thirty-third meeting held on August 1, 2001
4. Business arising from the minutes of the thirty-third meeting
On August 30, the Bureau of Biologics and Radiopharmaceuticals (BBR) held a press conference to announce its new exclusion guideline pursuant to the draft guideline described in the minutes of the August 1, 2001 Board of Directors meeting. Héma-Québec and CBS representatives attended the conference to answer questions from the media.
As implementation of these new criteria is quite recent, it is too soon to assess the repercussions. A follow-up will be made at the next meeting.
4.2. Anti-HBc: follow-up on implementation of anti-HBc screening test
The members of the Board of Directors asked the Executive Director to draft a letter to the BBR relating Héma-Québec's disappointment with the BBR's attitude, and more specifically, emphasizing that the BBR should have notified Héma-Québec sooner that it had to deal with another authority.
The Board of Directors reiterated its willingness to proceed with implementation of the anti-HBc screening tests.
Consequently, it was proposed, duly seconded and resolved that the resolution entitled "Reiteration of Board of Directors' willingness to implement anti-HBc screening tests" be adopted.
4.3. Stable product management: letter to National Advisory Committee on Transfusion Medicine (NACTM)
4.4. Invoicing hospitals: letter to Minister of State for Health and Social Services
4.5. Relocation of Québec City facility
Héma-Québec must now present a detailed plan of its needs to the persons in charge at Université Laval so that they can prepare an official proposal. Héma-Québec has thus set up the Québec construction steering committee.
Lastly, the Executive Director indicated that Héma-Québec would develop an alternate plan for relocating the Quebec City facility.
4.6. Public Board of Directors meeting
Following discussion, the members of the Board of Directors agreed to reconsider the format for the public meeting. The members of the Board will discuss a formula again. Several suggestions were made: discuss this matter again with the Liaison Committee; replace the meeting with an annual press briefing and enhance Héma-Québec's publications and web site.
The public meeting has been postponed to April 3, 2002.
It was proposed, duly seconded and unanimously resolved that the next public meeting be postponed to April 3, 2002.
5. Report on the week of September 11, 2001
Immediately following the events of September 11, 2001, Héma-Québec set up an emergency committee that has met twice a day until September 14, 2001. This emergency committee - made up of members of the Executive Committee, the Director, Québec City Facility Operations, and the Director, Industrial Safety - was mandated to assess the situation and keep abreast of the latest developments in order to respond quickly in an emergency.
More than 9,565 donors went to Héma-Québec clinics that week ? compared with about 5,000 donors in a normal week. Donor centres and mobile clinics extended their opening hours.
Nevertheless, the US did not require any blood components from Canada.
The Executive Director indicated that a study has been requested to assess the impact of this extraordinary week on donation habits, particularly the numerous first-time donors who went to give blood during that time.
6. Submission of five-year plan
He explained that the plan must be approved by the Board of Directors, but in view of the cancellation of the September 12, 2001 meeting, it was sent to the Minister of Health and Social Services after it was approved by the Chairperson of the Board of Directors.
He said that an increase of 5,000 units of red blood cells per year is expected until 2006-2007. Members suggested an annual increase in terms of percentage rather than an absolute number for red blood cells.
It was proposed, duly seconded and unanimously resolved that the five-year plan be adopted as submitted (a copy of which is appended hereto).
7. Project follow-up
8.2. Appointment of Dr. Jerry Teitel as Chairperson of the National Blood Safety Council
8.3. Adoption of Board of Directors' 2002 meeting schedule
It was proposed, duly seconded and unanimously resolved that the 2002 meeting schedule for Héma-Québec's Board of Directors be adopted (a copy of which is appended hereto).
8.4. Appointment of Safety Advisory Committee (SAC) observer
It was proposed, duly seconded and unanimously resolved that Robert Bédard be appointed acting observer of the Safety Advisory Committee. He may be replaced by a member from the public health sector when he is appointed to the Board of Directors by the Québec government to replace Dr. Paradis.
8.5. National Safety Council, in Winnipeg on November 1 and 2, 2001
8.6. Submission of NACTM letter: Hemolink
8.7. Stable product budget - recommendation from the Canadian Hemophilia Society
The Executive Director indicated that the main problem currently lies in the fact that no organization knows the invoicing process that will be implemented by the Minister of Health and Social Services. In this context, Héma-Québec considers the Procurement and Financing Management Committee to be the best authority for the Canadian Hemophilia Society to address.
The Executive Director will draft a letter to the assistant deputy minister of Public Health on behalf of the Board of Directors advising him of the concerns that were raised, specifically those by the Canadian Hemophilia Society, and that Héma-Québec would like to obtain details on the implementation of blood product invoicing.
8.8. Liability insurance renewal
Consequently, Héma-Québec will review its insurance structure this year and assess the possibility of implementing mechanisms to protect its insurance rates from market fluctuations.
9. Next meeting
Dr. André Lebrun
Dr. Francine Décary
RESOLUTION TO BE INTEGRATED INTO THE MINUTES OF THE HÉMA-QUÉBEC BOARD OF DIRECTORS MEETING OF OCTOBER 3, 2001
WHEREAS on January 31, 2001, the Board of Directors accepted the Safety Advisory Committee's recommendation to implement anti-HBc screening tests after a review of the impact of these tests on procurement, and mandated management to proceed to analyze the various implementation scenarios;
WHEREAS on June 6, 2001, the Board of Directors had analyzed the anti-HBc implementation options which were presented to them and selected the option to conduct these tests on new donors and reintegrate them on the basis of one positive anti-HBs test;
WHEREAS on September 27, 2001, Héma-Québec management presented the selected option to the Bureau of Biologics and Radiopharmaceuticals (BBR);
WHEREAS during this meeting, Héma-Québec management was notified by the BBR that this was a matter for the Medical Devices Bureau;
WHEREAS the Board of Directors is of the opinion that Héma-Québec must proceed with implementation of the anti-HBc screening tests;
IT IS RESOLVED: